Invest
Donate €100K to elimate cancer cell by cell with a new drug activated by light
We are offering a unique opportunity to invest €500,000 (or €100K from a group of 5 investors) for 5% equity in GenLumina. This funding (or Letter of Intent) will fast-track us from preclinical to clinical trials, bringing our groundbreaking cancer treatment closer to market.
Why this matters?
Breakthrough Potential
Our treatment has the power to change the cancer landscape.
Leverage
Your €500K could grow into €1.5M+ as we validate our approach.
Strategic Impact
Your investmentanchors a €10M valuation, unlocking another €4,5M in total funding, including crowdfunding and public co-financing.
We already secured 1 million euro for doing preclinicial research together with LUMC-hospital and Dutch Cancer Institute. Together, we can bring this life-saving treatment to those who need it most—faster.
Your donation or investment can be part of this transformative journey.
Venture Capital & Investors
We are seeking €5 million to advance from preclinical phase to the IND-ready/CTA phase, with colorectal cancer as our first target indication.
Investors gain a clear, structured investment approach, with regular updates as we progress toward market entry, making this an impactful and transparent opportunity.
Pharmaceutical Companies
A sub-licence for specific type of cancer that fits your portfolio. Our drug as payload to your targeting therapeutic or transform your imaging device into intervention device with precision treatment.
Together we make cancer a treatable disease, faster
Crowd funding
We are seeking €2 million to match with 3M on convertable loans in order to get a convincing preclinical dataset to convince partners to run clinical trails.
Supporters receive regular updates, invitations to exclusive events, and can witness how their contribution drives our work toward a medical breakthrough.
Donations
With a donation of €1000 or more, supporters can join our community and help fund our research and development.
Make impact . Together we push the bounderies of what is possible in precision oncology.
How Your Investment Will Be Utilized
Your investment will be strategically allocated to:
Clinical Trials
Launching studies to assess the safety and efficacy of our light-activated therapies across diverse cancer types.
Product Scaling
Building robust facilities to support large-scale production of our innovative treatment.
Market Integration
Establishing partnerships with healthcare networks and oncology clinics to integrate our therapies alongside standard treatments.
Key Milestones
Incubator Programs
2023-2024 – Successfully completed the Venture Academy, Unlock_ and Academic Startup Competition as incubator programs at BioScience Park in Leiden, equipping us with essential resources and connections.
Start-up Funding Support
Aug 2025 – Enterprise Leiden Fund (ELF) has contributed €35,000 to set up the basics of our company because grants and loans take longer and we don’t want to waste time to bring our solution to the market as soon as possible.
BioTechBooster – National Growth Fund
Sept 2024 – Collaborated with Leiden University’s Faculty of Science, securing €200,000 in funding for research on light-activated drugs with our academic partner Leiden University.
.
Patent Agreement
June 2025 – LURIS, the patent office of Leiden University, will hold a 15% equity stake in Genlumina, reflecting the innovative nature of our technology. GenLumina holds exclusive license agreement for all therapeutics worldwide. This license agreement is set up according to the National Deal Terms for universities in teh Netherlands.
UNIIQ – Accelarate technology
June 2025 – “These four startups (red: GenLumina o.a.) show how science, guts and entrepreneurship come together in Zuid-Holland. With investment of UNIIQ, we not only want to accelerate technology, but especially the impact these companies can make on health and deep tech/data innovation.” – Jasper Geselschap, Fund Manager UNIIQ
Health Holland – Joint research LUMC-hospital
July 2025 – A super important grant from Health Holland to do research together with Alexander Vahmeijer en Sven Mieog from Image Guided Surgery at LUMC with their peptide to identify colorectal cancer with and our drug as payload.
.